Discontinuation of Evrenzo development for chemotherapy-associated anemia
An individual drug development program for Evrenzo involving Phase 2 development for chemotherapy-associated anemia, which was discontinued in 2023, with an impairment loss recognized following a review of future plans.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.